证券日报网讯 1月22日，之江生物发布公告称，公司预计2025年年度实现归属于母公司所有者的净利 润-3，200.00万元到-4，700.00万元，与上年同期相比净利润将减少亏损8，046.21万元到9，546.21万 元，同比减亏幅度63.13%到74.89%。 （文章来源：证券日报） ...

Major Announcements - Zhaoyi Innovation plans to use 500 million CNY of A-share fundraising to increase capital in its wholly-owned subsidiaries for the implementation of the DRAM project [1] - Haiguang Information's mid-2025 profit distribution plan includes a cash dividend of 0.09 CNY per share, totaling 209 million CNY [2] - *ST Biology has terminated the major asset restructuring plan to acquire 51% of Hunan Huize Biomedical Technology Co., Ltd. [3] - Fosun Pharma intends to spin off its subsidiary Fosun Antigen for independent listing on the Hong Kong Stock Exchange [4] - Jingchen Co. has set the inquiry transfer price at 82.85 CNY per share for the transfer of 13.1 million shares [5] Performance Forecasts - Zhaoyi Innovation expects a net profit of approximately 1.61 billion CNY for 2025, a year-on-year increase of about 46% [9] - Longying Precision anticipates a net profit decrease of 17.70% to 29.36% for 2025, estimating between 545 million CNY and 635 million CNY [9] - Ruichuang Micro-Nano forecasts a net profit of around 1.1 billion CNY for 2025, representing a 93% increase [10] - Nanjing Bank projects a net profit of 21.81 billion CNY for 2025, an 8.08% increase year-on-year [11] - Zhongyuan Co. expects a net profit increase of 80% to 105% for 2025, estimating between 139 million CNY and 158 million CNY [12] - Qiangyi Co. anticipates a net profit increase of 57.87% to 71.17% for 2025, estimating between 368 million CNY and 399 million CNY [13] - Liard expects a net profit of 300 million CNY to 380 million CNY for 2025, turning from a loss of 889 million CNY in the previous year [14] - Daheng Technology forecasts a net profit of approximately 106 million CNY for 2025, also turning from a loss [16] - Dongfeng Co. anticipates a net loss of 390 million CNY to 480 million CNY for 2025 [17] - Qing Song Co. expects a net profit increase of 137.73% to 201.74% for 2025, estimating between 130 million CNY and 165 million CNY [18] - SIRUI Co. forecasts a net profit of 165 million CNY to 184 million CNY for 2025, turning from a loss [19] - Shengmei Shanghai expects a revenue increase of 18.91% to 22.47% for 2025, estimating between 6.68 billion CNY and 6.88 billion CNY [20] - Yijun Co. anticipates a net loss of 11 million CNY to 14 million CNY for 2025 [21] - Saint Yuan Environmental Protection expects a net profit increase of 31.79% to 59.24% for 2025, estimating between 240 million CNY and 290 million CNY [22] - Lijun Co. forecasts a net profit decrease of 45.05% to 60.03% for 2025, estimating between 4.8 million CNY and 6.6 million CNY [23] - Xingqi Eye Medicine expects a net profit increase of 95.82% to 121.56% for 2025, estimating between 662 million CNY and 749 million CNY [25] - Beidou Star expects a net loss of 230 million CNY to 290 million CNY for 2025, reducing losses compared to the previous year [26] - Yiling Pharmaceutical anticipates a net profit of 1.2 billion CNY to 1.3 billion CNY for 2025, turning from a loss of 725 million CNY [27] - Zhijiang Bio forecasts a net loss of 32 million CNY to 47 million CNY for 2025, reducing losses compared to the previous year [28] - Yema Battery expects a net profit decrease of 58% to 70% for 2025, estimating between 45.83 million CNY and 64.17 million CNY [29] - Yunmei Energy anticipates a net loss of 410 million CNY to 470 million CNY for 2025 [30] - Yingfang Micro expects a net loss of 69 million CNY to 97 million CNY for 2025 [31] - Guanghua Technology forecasts a net profit of 85 million CNY to 120 million CNY for 2025, turning from a loss [33] Share Buybacks - Hengyi Petrochemical plans to repurchase shares worth 500 million CNY to 1 billion CNY [34] - Yunyi Electric plans to repurchase shares worth 100 million CNY to 150 million CNY [34] - Xidun Pharmaceutical plans to repurchase shares worth 25 million CNY to 50 million CNY [35]

Group 1 - Huakang Clean announced it is the first candidate for the bid of the Wuhan First Hospital expansion project with a bid amount of 54.88 million yuan and a construction period of 120 days [1] - Hualing Steel's subsidiary plans to invest 449.88 million yuan in a major overhaul project for its coking plant, aiming to address aging issues and restore production capacity over a 19-month construction period [2] - Yinjia Technology expects a net loss of 140 million to 110 million yuan for 2025, compared to a loss of 129 million yuan in the previous year [3] Group 2 - Guochuang High-tech forecasts a net profit of 16 million to 24 million yuan for 2025, recovering from a loss of 58.52 million yuan in the previous year [4] - Shiyi Da anticipates a net profit increase of 31 million to 46 million yuan for 2025, turning around from a loss of 23.41 million yuan last year [5] - Lijun Co. expects a net profit of 48 million to 66 million yuan for 2025, representing a decline of 45.05% to 60.03% compared to the previous year [7] Group 3 - Xindian Pharmaceutical plans to repurchase shares worth 25 million to 50 million yuan for employee stock ownership plans or equity incentives, with a maximum repurchase price of 42 yuan per share [6] - Jingchen Co. has set the initial transfer price for its shares at 82.85 yuan per share, with a total of 13.1 million shares to be transferred to 28 institutional investors [8] - Zejing Pharmaceutical received approval for clinical trials of its innovative cancer immunotherapy drug ZG005 in combination with platinum-based chemotherapy for advanced nasopharyngeal and esophageal squamous cell carcinoma [9] Group 4 - Xingqi Eye Medicine expects a net profit of 662 million to 749 million yuan for 2025, marking a growth of 95.82% to 121.56% compared to the previous year [10] - Liancheng Precision anticipates a net loss of 12 million to 17 million yuan for 2025, reducing its loss from 37.96 million yuan in the previous year [11] - Beidou Star expects a net loss of 230 million to 290 million yuan for 2025, improving from a loss of 350 million yuan last year [13] Group 5 - Qing Shan Paper's affiliate won a bid for a wastewater treatment project worth 51.9 million yuan [15] - Yiling Pharmaceutical forecasts a net profit of 1.2 billion to 1.3 billion yuan for 2025, recovering from a loss of 725 million yuan in the previous year [16] - Huahai Pharmaceutical received a drug registration certificate for its product used in treating depression and obsessive-compulsive disorder [23] Group 6 - Nanjing Panda expects a net profit of 10 million to 15 million yuan for 2025, turning around from a loss of 189 million yuan last year [40] - Rui Sheng Intelligent anticipates a net profit of 33.92 million to 38.40 million yuan for 2025, representing a growth of 112% to 140% compared to the previous year [41] - Jiechang Drive expects a net profit of 395 million to 437 million yuan for 2025, with a growth of 40% to 55% compared to the previous year [43]

人民财讯1月22日电，之江生物(688317)1月22日发布业绩预告，预计2025年归母净利润亏损3200万元— 4700万元，同比减亏63.13%—74.89%。公司2025年度亏损收窄的原因为主要是资产减值损失的减少和 成本费用控制措施的有效实施。 ...

Core Viewpoint - Zhijiang Biology (688317.SH) forecasts a net profit attributable to shareholders of the parent company for 2025 to be between -32 million and -47 million yuan, indicating a significant loss compared to the previous year [1] Financial Performance - The expected net profit loss represents an increase in losses by 80.4621 million to 95.4621 million yuan compared to the same period last year, reflecting a year-on-year reduction in losses of 63.13% to 74.89% [1] Reasons for Loss - The primary reasons for the company's performance losses include a decline in sales of main products, the implementation of centralized procurement policies leading to price reductions, and an increase in the value-added tax rate for self-produced reagent products to 13%, resulting in decreased revenue [1] - Additional factors contributing to the losses include a decline in financial income and reduced foreign exchange gains [1] Strategic Response - The company is actively responding to market competition by enhancing product research and development, optimizing cost reduction and efficiency measures, and exploring potential opportunities to continuously improve product competitiveness and operational capabilities [1]

Core Viewpoint - Zhijiang Biotech (688317.SH) is expected to report a net loss attributable to shareholders of the parent company for the year 2025, with estimates ranging from -32 million to -47 million yuan, indicating a significant decline in profitability compared to the previous year [1] Financial Performance - The projected net loss represents an increase in losses of 80.46 million to 95.46 million yuan compared to the same period last year, reflecting a year-on-year reduction in loss margin of 63.13% to 74.89% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be between -39 million and -58 million yuan, with a reduction in losses of 70.27 million to 89.27 million yuan compared to the previous year, indicating a year-on-year reduction in loss margin of 54.78% to 69.60% [1] Reasons for Performance - The primary reasons for the company's expected losses include a decline in sales of main products, the implementation of centralized procurement policies leading to price reductions, and an increase in the value-added tax rate on self-produced reagent products to 13%, which has negatively impacted revenue [1] - Additional factors contributing to the losses include a decrease in financial income and reduced foreign exchange gains [1] Strategic Response - The company is actively responding to market competition by enhancing product research and development, optimizing cost reduction and efficiency measures, and exploring potential opportunities to continuously improve product competitiveness and operational capabilities [1] - The narrowing of losses this year is attributed to a reduction in asset impairment losses and the effective implementation of cost control measures [1]

Core Viewpoint - Zhijiang Biotechnology (688317.SH) is expected to report a net loss attributable to shareholders of the parent company for the year 2025, with estimates ranging from -32 million to -47 million yuan, indicating a significant decline in profitability compared to the previous year [1] Financial Performance - The projected net loss represents an increase in loss of 80.4621 million to 95.4621 million yuan compared to the same period last year, reflecting a year-on-year reduction in loss margin of 63.13% to 74.89% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be between -39 million and -58 million yuan, with a reduction in loss of 70.2713 million to 89.2713 million yuan compared to the previous year, indicating a year-on-year reduction in loss margin of 54.78% to 69.60% [1] Reasons for Performance - The primary reasons for the company's expected losses include a decline in sales of main products, the implementation of centralized procurement policies leading to price reductions, and an increase in the value-added tax rate on self-produced reagent products to 13%, which has negatively impacted revenue [1] - Additionally, a decrease in financial income and foreign exchange gains has contributed to the overall performance decline [1] Strategic Response - The company is actively responding to market competition by enhancing product research and development, optimizing cost reduction and efficiency measures, and exploring potential opportunities to continuously improve product competitiveness and operational capabilities [1] - The narrowing of losses this year is attributed to a reduction in asset impairment losses and the effective implementation of cost control measures [1]

Financial Performance - The company expects a net loss attributable to shareholders of the parent company for 2025 to be between -32 million and -47 million yuan, representing a decrease in loss of 63.13% to 74.89% compared to the previous year [2]. - The net loss attributable to shareholders after deducting non-recurring gains and losses is projected to be between -39 million and -58 million yuan, with a reduction in loss of 54.78% to 69.60% year-on-year [2]. - The total profit for the previous year was -150.57 million yuan, with a net profit attributable to shareholders of -127.46 million yuan [3]. Reasons for Losses - The main reasons for the current period's losses include a decline in product sales, price reductions due to centralized procurement policies, and an increase in VAT for self-produced reagent products [4]. Loss Mitigation - The narrowing of losses this year is attributed to a decrease in asset impairment losses and effective cost control measures [4]. Forecast Accuracy - The company has not identified any significant uncertainties affecting the accuracy of this earnings forecast as of the announcement date [5]. - The forecast data is preliminary and the final audited financial data will be disclosed in the official 2025 annual report [6].

Core Viewpoint - Zhijiang Biotech (688317.SH) forecasts a net profit attributable to shareholders of the parent company for 2025 to be between -32 million to -47 million yuan, indicating a significant loss compared to the previous year [1] Financial Performance - The expected net profit loss represents an increase in loss of 80.4621 million to 95.4621 million yuan year-on-year, reflecting a reduction in loss margin of 63.13% to 74.89% [1] Reasons for Performance Decline - The primary reasons for the company's performance decline include a decrease in sales of main products, the implementation of centralized procurement policies leading to price reductions, and an increase in the value-added tax rate for self-produced reagent products to 13%, resulting in decreased revenue [1] - Additional factors contributing to the loss include a decline in financial income and reduced foreign exchange gains [1] Strategic Response - The company is actively responding to market competition by enhancing product research and development, optimizing cost reduction and efficiency measures, and exploring potential opportunities to continuously improve product competitiveness and operational capabilities [1]

之江生物公告，预计2025年年度实现归属于母公司所有者的净利润将出现亏损，预计实现归属于母公司 所有者的净利润-3200万元到-4700万元。与上年同期相比，净利润将减少亏损8046.21万元到9546.21万 元，同比减亏幅度63.13%到74.89%。 ...